Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report.

ABSTRACT:

Introduction

Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis. It selectively blocks the p19 subunit of the IL-23 pathway, leading to reduced keratinocyte proliferation reducing the inflammatory response.

Case presentation

We present a case of de novo vitiligo in a patient being treated with risankizumab-rzaa (Skyrizi) for plaque psoriasis. Our patient had extensive plaque psoriasis affecting his trunk, upper extremities, and scalp, encompassing 30% of his total body surface area. He was treated with risankizumab-rzaa, an IL-23 inhibitor, with significant improvement of his psoriasis and residual hyperpigmented, post-inflammatory patches. In addition, he developed new-onset vitiligo, for which he decl

SUBMITTER: Thomas KV 

PROVIDER: S-EPMC12823106 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature